---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-004927"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2024-04-10T23:59:59+00:00"
generated_at: "2026-06-04T00:29:03.279975+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics clears IND for APR-1051; updates on ATRN-119 Phase 1 at AACR

## Summary
- IND for next-gen WEE1 inhibitor APR-1051 cleared; first patient dosing expected June 2024 in Phase 1 ACESOT-1051 trial.
- ATRN-119 (ATR inhibitor) Phase 1/2a: enrolling 550 mg cohort; no DLTs, no Grade 4+ AEs; stable disease in two patients (one on treatment 188+ days).
- Preclinical data show APR-1051 has >50-fold reduced PLK off-target inhibition vs ZN-c3; well tolerated with minimal hematotoxicity in mice.
- New preclinical ATRN-333 combination with lomustine for glioblastoma shows synergy; intracranial delivery via convection-enhanced device.

## SEC filing metadata
- accession: 0001558370-24-004927
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2024-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837024004927/0001558370-24-004927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837024004927/apre-20240410x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-004927
- JSON: https://secwatch.observer/filing/0001558370-24-004927.json
- Plain text: https://secwatch.observer/filing/0001558370-24-004927.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.